nivolumab,ipilimumab,cabozantinib
bms
['nivolumab', 'rcc,(-irccs),(-srcc),(-urcc)', ' ipi ', '#gu,(-#gui),(-#gunagratinib),(-#guard),(-#gut)', 'cabo ', 'nivo', 'cosmic 313', 'cosmic-313']
cosmic 313 cabo+nivo+ipi (c+n+i) first line rcc intermediate or poor risk presentation , triplet therapy pfs was improved hr 0.63 in intermediate risk pt, but not poor risk pts. grade 3/4 trae occurred in 74% triplet therapy c+n+i patients vs 42% in p+n+i #gu23 
@UroOnc fellow @FCUroOnc @caseurology @JohnsHopkinsSPH grad/👦👦👦🐶mom/Health outcomes/translational 🔬 bladder@AbboshLab 🧪 Immunology @DrexelUniv